Chembio Diagnostics, Inc. (CEMI.OB)'s DPP®HIV-Syphilis Multiplex Test Demonstrates 100% Sensitivity and Specificity in Evaluation by Mexico's Institute of Epidemiological Diagnosis and Reference
5/14/2013 9:20:11 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MEDFORD, N.Y., May 14, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, announces receipt of an evaluation report from Mexico's Institute of Epidemiological Diagnosis and Reference (InDRE) regarding the Company's DPP® HIV-Syphilis multiplex test, which showed the Company's assay performed with 100% agreement for both markers on all 941 samples tested.
Help employers find you! Check out all the jobs and post your resume.
comments powered by